异常凝血酶原联合CEACA74和CA199在胃癌诊治-肿瘤防治研究.pdf

2018 45 6  Cancer Res Prev Treat,2018,Vol.45,No.6 395 肿瘤防治研究 年第 卷第 期 · · doi:10.3971/j.issn.1000-8578.2018.17.1007 ·临床诊断· 异常凝血酶原联合CEA 、CA72-4和CA199 在胃癌诊治中的价值 蔡晓娟，王堃，喻晶 Clinical Value of Abnormal Prothrombin Combined with CEA, CA72-4 and CA199 on Patients with Gastric Cancer CAI Xiaojuan, WANG Kun, YU Jing Department of Clinical Laboratory, Hubei Cancer Hospital, Clinical Colorectal Cancer Study Center, Wuhan Clinical Colorectal Cancer Study Center, Wuhan 430079, China Corresponding Author: YU Jing, E-mail: yujings9774@ Abstract: Objective To evaluate the clinical value of abnormal prothrombin (PIVKA- ) combined with Ⅱ CEA, CA199 and CA72-4 on the diagnosis, treatment, recurrence and metastasis of patients with gastric cancer. Methods Serum PIVKA- , CEA, CA72-4, CA199 levels in 123 gastric cancer patients, 80 healthy Ⅱ controls and 30 benign gastric diseases patients were performed by chemiluminescent immunoassay(CLIA), electrochemiluminescence immunoassay (ECLIA), respectively. And random 20 patients with gastric cancer were followed up. Results The level of PIVKA- was significantly higher in gastric cancer group than Ⅱ those in benign gastric disease group and healthy control group (all P0.001). ROC analysis showed the cut- off value to discriminate cancer from control was established at 32.14U/L for PIVKA- Ⅱ(sensitivity (39.84%), specificity (95%)). The sensitivity of PIVKA- was not significantly higher than CEA, CA199 or CA72-4, Ⅱ while the specificity was slightly lower. With the rising of gastric carcinoma stage, the levels of PIVKA- Ⅱ as well as the positive rate were increased (all P0.05). Elevated